

**A 01**

CODING FORMS FOR SRC INDEXING

Microfiche No.		OTS0559846	
New Doc ID		Old Doc ID	
88000000039		8EHQ-1199-14599	
Date Produced	Date Received	TSCA Section	
01/18/83	11/26/99	8E	
Submitting Organization			
BAYER CORP			
Contractor			
BAYER AG, INSTITUT FUR TOXICOL			
Document Title			
INITIAL SUBMISSION: ISODODEKAN, SUBCHRONISCHE TOXIKOLOGISCHE UNTERSUCHUNGEN AN RATTEN (VERSUCH MIT SCHLUNDSONDEN- APPLIKATION UBER 3 MONATE), W/TSCA COVER SHEET DATED 111899			
Chemical Category			
ISODODECANE			

**B 01**

A 02

# INITIAL SUB- MISSION

B 02

A 03

8EHQ-1199-14599

TSCA HEALTH & SAFETY STUDY COVER SHEET

TSCA CBI STATUS:

-CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (if Contains CBI) Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

RECEIVED  
EPA-77-DBIC  
1999 NOV 26 AM 11:35

<b>1.0 SUBMISSION TYPE</b> - Contains CBI <input type="checkbox"/> 8(d) <input checked="" type="checkbox"/> 8(e) <input type="checkbox"/> FYI <input type="checkbox"/> 4 <input type="checkbox"/> OTHER: Specify _____ <input type="checkbox"/> Initial Submission <input type="checkbox"/> Follow-up Submission <input type="checkbox"/> Final Report Submission Previous EPA Submission Number or Title if update or follow-up: _____ Docket Number, if any: # _____ <input type="checkbox"/> continuation sheet attached		
<b>2.1 SUMMARY/ABSTRACT ATTACHED</b> (may be required for 8(e): optional for 8(d) & FYI) <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	<b>2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID</b> Cert# P 917006943 (XXXXXX)	<b>2.3 FOR EPA USE ONLY</b>
<b>3.0 CHEMICAL/TEST SUBSTANCE IDENTITY</b> - Contains CBI Reported Chemical Name (specify nomenclature if other than CAS name): <u>CAS: 111-201-8</u> Purity _____ % <input type="checkbox"/> Single Ingredient <input checked="" type="checkbox"/> Commercial/Tech Grade <input type="checkbox"/> Mixture Trade Name: <u>_____</u> Common Name: _____		
<b>4.0 REPORT/STUDY TITLE</b> - Contains CBI Subchronic Toxicological Investigations on Rats (Investigation with pharyngeal tube over 3 months) Report # 11462 <input type="checkbox"/> Continuation sheet attached		
<b>5.1 STUDY/TSCATS INDEXING TERMS</b> [CHECK ONE] HEALTH EFFECTS (HE): <input checked="" type="checkbox"/> ENVIRONMENTAL EFFECTS (EE): _____ ENVIRONMENTAL FATE (EF): _____		
<b>5.2 STUDY/TSCATS INDEXING TERMS</b> (see instructions for 4 digit codes) STUDY SUBJECT ROUTE OF EXPOSURE (HE only): _____ VEHICLE OF EXPOSURE (HE only): _____ TYPE: <u>STOX</u> ORGANISM (HE, EE only): <u>RATS</u> EXPOSURE (HE only): _____ Other: _____ Other: _____ Other: _____ Other: _____		
<b>6.0 REPORT/STUDY INFORMATION</b> <input type="checkbox"/> Contains CBI - Study is GLP Laboratory: <u>Bayer Ag - Institute for Toxicology, Wuppertal</u> Report/Study Date: <u>1/18/83</u> Source of Data/Study Sponsor (if different than submitter): <u>Bayer AG</u> Number of pages: <u>131</u> <input type="checkbox"/> continuation sheet attached		
<b>7.0 SUBMITTER INFORMATION</b> <input type="checkbox"/> Contains CBI Submitter: <u>Donald W. Lamb, Ph.D</u> Title: <u>V. P., Prod. Safety &amp; Reg. Affrs</u> Phone: <u>412-777-7431</u> Company Name: <u>Bayer Corporation</u> Company Address: <u>100 Bayer Road</u> <u>Pittsburgh, PA 15205-9741</u> Submitter Address (if different): _____ Technical Contact: <u>Donald W. Lamb, Ph.D</u> Phone: <u>(412)777-7431</u> <input type="checkbox"/> continuation sheet attached		
<b>8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> continuation sheet attached		

Contain. NO CBI

RECEIVED  
EPA/PT/NCIC  
99 DEC 10 AM 11:22



Submitter Signature: Donald W. Lamb Date: 11/18/99

Page 1 of 2



BEHQ-99-14599

28960

B 03

9.0 CONTINUATION SHEET  
Submitter Tracking Number/Internal ID

P917006943  
99-2-75

CONTINUED FROM COVER SHEET SECTION # 2.1

**TSCA 8(e) Evaluation:**

Based on the damage to the liver and kidney reported in the abstract, thus we are reporting .

**Abstract**

1. Each of 20 male and 20 female rats received Isododecane by pharyngeal tube for 3 months in the following concentrations: 0 (control), 330, 1000 and 3000 mg/kg.
2. Reaction and mortality of male and female rats was not affected with doses up to 3000 mg/kg. From a dose of 1000 mg/kg on, growth of male and female animals was delayed. From 330 mg/kg on water consumption and from 1000 mg/kg on food consumption was elevated.
3. The blood was not affected by Isododecane in the dose groups up to 1000 mg/kg. After 3000 mg/kg, there was a decrease in the number of erythrocytes, hemoglobin content, and hematocrit.
4. From 330 mg/kg on there was indication of a treatment effect on the liver. Based on changes observed in the liver parenchyma, damage to the liver could be assumed at 1000 mg/kg.
5. Urine testing, clinical-chemical analyses, sections and histopathological investigations revealed treatment effects on the kidneys of male animals at 330 mg/kg.
6. Blood sugar, cholesterol, and triglyceride concentrations in the rats were in the normal range up to the 3000 mg/kg dose group.
7. Sections and histopathological investigations in the groups revealed no criteria for other treatment specific changes in the organs up to 3000 mg/kg.
8. Isododecane was therefore tolerated by female rats with the 330 mg/kg dose without damage with the treatment described.